EUVIMEDEUVIMED entdecken
Open Access

Engineering exhaustion-resistance CD19 CAR T cells to address translational barriers for the treatment of cancer and autoimmune disease

Afreen Asif Ali Sayed iD, Tim Chan iD, Cheryl G Bolinger iD, Pooja Chauhan iD, Marion Chakiath iD, Carol Poortman iD, Jacques Plummer iD, Bernward Klocke iD, Enayat Nikoopour iD, Aifen Wang iD, Tikva Dadon iD, David Woessner iD und 7 weitere

Science Advances · 13.11.2026 · 12 (46)

DOI: 10.1126/sciadv.aej2663 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 13.11.2026. Verfasst von Afreen Asif Ali Sayed und 18 weiteren Autor:innen. Beteiligte Einrichtung: Precigen, 20358 Seneca Meadows Pkwy, Germantown, MD 20876, USA. Hauptthemen laut MEDLINE: Antigens, CD19, Neoplasms, Autoimmune Diseases, Immunotherapy, Adoptive. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Precigen. Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PRGN-3008 is a CD19 CAR T cell designed to overcome key limitations in ex vivo and in vivo CAR T manufacturing, cost, safety, and therapeutic durability. Featuring decentralized overnight manufacturing without ex vivo expansion, PRGN-3008 is engineered using a single nonviral transposon to encode CD19 CAR, membrane-bound interleukin-15 (mbIL-15) for improved persistence, PD-1–targeting microRNAs to prevent exhaustion, and an inducible safety switch for controlled in vivo elimination. Safety studies showed low vector copy numbers, favorable integration profile, and efficient CAR T ablation upon safety-switch activation. The combined mbIL-15 expression and PD-1 down-regulation preserved PRGN-3008 polyfunctionality and sustained cytotoxicity across repeated tumor challenges, outperforming nonarmored or singly modified CAR T cells. In xenograft models, overnight-manufactured PRGN-3008 without ex vivo expansion and activation achieved durable tumor clearance, prolonged tumor-free survival, robust antigen dependent expansion, and enrichment of memory T cell phenotypes linked to clinical durability. Notably, PRGN-3008 generated from heavily pretreated patients with systemic lupus erythematosus or lupus nephritis, maintained effector function, resisted terminal differentiation under chronic antigen exposure, and effectively depleted autoreactive B cells in a humanized mouse model. Transcriptomic analysis revealed that the combination of mbIL-15 expression and PD-1 down-regulation enhances the expression of genes associated with bioenergetic pathways, including oxidative phosphorylation, mitochondrial biogenesis, glycolysis, and glutamine utilization, thereby supporting resistance to exhaustion and sustained effector function. Collectively, these data support PRGN-3008 as a clinically translatable, scalable, and controllable CAR T with the potential to expand access to cell therapy across oncology and autoimmune indications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19NeoplasmsAutoimmune DiseasesImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumansAnimalsT-Cell ExhaustionMiceInterleukin-15Xenograft Model Antitumor AssaysProgrammed Cell Death 1 Receptor

Substanzen

Antigens, CD19Receptors, Chimeric AntigenInterleukin-15Programmed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Precigen, 20358 Seneca Meadows Pkwy, Germantown, MD 20876, USA.

ORCID-Profile: Afreen Asif Ali Sayed, Tim Chan, Cheryl G Bolinger, Pooja Chauhan, Marion Chakiath, Carol Poortman, Jacques Plummer, Bernward Klocke, Enayat Nikoopour, Aifen Wang, Tikva Dadon, David Woessner, Woo Joo, Christian Zinser, Roshanak Tolouei Semnani, Rutul R Shah, Helen Sabzevari, Douglas E Brough, Shamim Ahmad

Förderung

  • Precigen. Inc.

Zitieren

APA

Sayed, A. A. A., Chan, T., Bolinger, C. G., Chauhan, P., Chakiath, M., Poortman, C., Plummer, J., Klocke, B., Nikoopour, E., Wang, A., Dadon, T., Woessner, D., Joo, W., Zinser, C., Semnani, R. T., Shah, R. R., Sabzevari, H., Brough, D. E., & Ahmad, S. (2026). Engineering exhaustion-resistance CD19 CAR T cells to address translational barriers for the treatment of cancer and autoimmune disease. Science Advances, 12(46). https://doi.org/10.1126/sciadv.aej2663

Vancouver

Sayed AAA, Chan T, Bolinger CG, Chauhan P, Chakiath M, Poortman C, et al. Engineering exhaustion-resistance CD19 CAR T cells to address translational barriers for the treatment of cancer and autoimmune disease. Science Advances. 2026;12(46). doi:10.1126/sciadv.aej2663

BibTeX
@article{Sayed2026,
  author = {Sayed, Afreen Asif Ali and Chan, Tim and Bolinger, Cheryl G and Chauhan, Pooja and Chakiath, Marion and Poortman, Carol and Plummer, Jacques and Klocke, Bernward and Nikoopour, Enayat and Wang, Aifen and Dadon, Tikva and Woessner, David and Joo, Woo and Zinser, Christian and Semnani, Roshanak Tolouei and Shah, Rutul R and Sabzevari, Helen and Brough, Douglas E and Ahmad, Shamim},
  title = {Engineering exhaustion-resistance CD19 CAR T cells to address translational barriers for the treatment of cancer and autoimmune disease},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {46},
  doi = {10.1126/sciadv.aej2663}
}
Kostenlos starten →